Strategic Intelligence: Orphan Designated Drugs

Strategic Intelligence: Orphan Designated Drugs

Summary

This report consolidates GlobalData’s latest thinking and forecasts around how the healthcare, macroeconomic, technology, and regulatory trends will impact the orphan designated drugs in pharma space, as well as providing insights into the leading players and future challengers across the value chain, and providing insights into key drugs and markets from GlobalData’s Pharma Intelligence Center. Additionally, this report is designed to provide strategic planners, competitive intelligence professionals and key stakeholders in the pharmaceutical industry a clear view of the opportunities and risks over the foreseeable future.

Due to the unmet medical demands of many rare diseases around the world, the number of orphan designated drugs (ODD) by regulatory agencies such as the FDA and EMA has increased in recent years. This has arisen from international recognition of the significant number of people that rare diseases affect daily, paired with limited therapeutic options and low patient populations.

As a result, a wide variety of pharmaceutical companies are expanding their orphan drug portfolio through co-development partnerships and collaborations, innovative means of personalized and precision therapy, as well as receiving financial and legal support from regulatory bodies to meet this unmet medical need.

Scope

• A dedicated report examining the pivotal healthcare, technological, macroeconomic, and regulatory trends shaping the orphan designated drugs field in pharma landscape.
• This report also provides an in-depth analysis of how these trends are poised to either accelerate progress or create obstacles for the growth of the orphan designated drugs market.

• Understand the key trends accelerating or hindering the orphan designated drugs in pharma space.